EMEA-001045-PIP04-18 - paediatric investigation plan

sarilumab

Key facts

• Invented name:
  • Kevzara
  • Kevzara
• Active substance:
  sarilumab
• Therapeutic area:
  Immunology-Rheumatology-Transplantation
• Decision number:
  P/0356/2018
• PIP number:
  EMEA-001045-PIP04-18
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Treatment of polymyalgia rheumatica
• Route(s) of administration:
  Subcutaneous use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  07/12/2018
• Compliance check done:
  No

Decision

P/0356/2018: EMA decision of 7 December 2018 on the granting of a product specific waiver for sarilumab (Kevzara), (EMEA-001045-PIP04-18)

Adopted Reference Number: EMA/812158/2018